- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
![]()
PLAY BUTTON
![]()
PLAY BUTTON
![]()
86 Cards in this Set
- Front
- Back
|
Half life of glucogon
|
3-6 minutes
|
|
Mechanism of influence of alpha and beta pancreatic cells on each other
|
Beta cells inhibit alpha cells through endocrine mechanisms and alpha cells inhibit beta through paracrine mechanisms
|
|
Chromosome of preprosomatostatin
|
Long arm of chromosome 3
|
|
What somatostatin is released be the anterior pituitary?
|
SS-14, inhibits the release of growth hormone.
|
|
What growth hormone inhibitor is released by the gut
|
prosomatostatin, SS-28. 7-10 times more potent in inhibiting GH release then SS-14
|
|
Tolbutamide?
|
sulfonylurea drug that increases insulin secretion and pancreatic somatostatin, SS-28.
|
|
What metabolites increase somatostatin release?
|
glucose, arginine, and leucine. Similar to what causes the release of Insulin
|
|
What hormones cause the release of somatostatin?
|
glucogon, vasoactive intestinal peptide, cholecystikinin. NOT insulin.
|
|
Somatostatin receptor type?
|
inhibitory heterotrimeric G protein receptors. As a result cAMP is inhibited and PKA inactivated.
|
|
Sarotonin secreting tumor?
|
Carcinoid tumor
|
|
Half life of native somatostatin
|
3 minutes.
|
|
Octreotide?
|
Somatostatin variant with a half life of 110 minutes.
|
|
One line that sums up somatostatin?
|
It inhibits the secretion of a lot of hormones.
|
|
Clinical use of synthetic somatostatin?
|
Treat GH secreting neoplasm
|
|
Cause of gigantism
|
GH secreting tumor before closure of long bone growth centers.
|
|
Cause of acromegly
|
excess GH chronically secretes after the closure of long bone growth plates
|
|
Pegvisomant
|
GH receptor antagonist
|
|
Release of ILG in response to ?
|
GH
|
|
location of gene for GH
|
chromosome 17
|
|
Cells that produce GH?
|
somatotrophs located in the lateral area of the anterior pituitary
|
|
Most abundant hormone of the anterior pituitary?
|
GH
|
|
How does an oral glucose load suppress GH?
|
glucose causes the release somatostatin which in turn suppresses GH release
|
|
What stimulates the hypothalamus to secrete GHRH?
|
low glucose, increase in AA, sleep, exercise, stress
|
|
Rise in IGH-1
|
contributes to cell multiplication and differentiation. Leads to skeletal muscle and visceral growth.
|
|
other name for GHRH
|
Somatocrinin
|
|
GHRH receptor mechanism?
|
Increase cAMP and calcium-calmudulin stimulation.
|
|
Negative feed back of GH?
|
liver derived IGF-1, Increase in glucose
|
|
Main AA stimulator of GH
|
Arginine
|
|
Pharmacologic stimulators of GH
|
GHRH, estrogens, Alpha agonists, Beta antagonists, Dopamine agonists, K infusion, Seritonin precursers.
|
|
Pharmacologic suppressers of GH
|
somatostatin, progesterone, Alpha antagonists, beta agonists, dopamine antagonists, GH and IGF-1
|
|
Pathologic stimulation of GH
|
starnation, anorexia, ectopic GHRH production, acromegaly, chronic renal failure, hypoglycemia.
|
|
pathologic GH supressers
|
obesity hypo and hyper thyroidism
|
|
What may inhibit GH response to falling glucose or arginine
|
fatty acids
|
|
What does growth hormone do to available energy
|
it make FFA available to tissues to use as energy so glucose and amino acids are available for growth
|
|
Endocrine disease associated with chronic hyper-secretion of GH
|
DM
|
|
GH affect on the liver
|
secretion of IGF-1, increase gluconeogenisis, Increase glycogen synthesis. The glycerol from lypolisis is used for gluconeogenisis.
|
|
GH effect on growth plate of long bones
|
growth
|
|
GH effect on adipose tissue
|
lipolysis. GH increases the sensitivity of the adipose tissues to the actions of catecholamines and decreases its lipogenic response to insulin. Impairs the glucose uptake by post-receptor insulin inhibition.
|
|
GH effect on muscles
|
decreased glucose uptake, increased protein synthesis. The increases FFA are prefferentially used for fuel by the mucle suppressing the glucose uptake. AA uptake is increased for protein synthesis.
|
|
IGF receptor
|
The receptor is bound to a tyrosine kinase that activates the JAK/STat cascade which results in the activation of transcription factors and increased mitogenic response.
|
|
Somatomedians
|
IGFs
|
|
Effect of IGF
|
causes the same response as insulin but are more potents in there growth promotion.
|
|
Long term effects linked to high levels of IGF-1
|
development of colon, breast, prostate, and lung cancer.
|
|
Regulation of synthesis of IGF 1 and 2
|
IGF 1 is regulated by GH and IGF 2 from hepatic production is independent of GH control
|
|
Precursor for catecholamines
|
tyrosine
|
|
Release of catecholamines
|
AP arrives at the terminal end of the neuron and causes release of Ach which bind to nicotinic receptors on the adrenal medulla, this casues an influx of calcium and the release of epi and norepi from the chromaffin granules.
|
|
Metabolic effects of catecholamines
|
they are counter-regulatory hormones that have metabolic effects directed toward mobilizing fulels from storage for oxidation to meet the increased energy requirements of acute and chronic stress.
|
|
What causes the release of corticotrophin releasing hormone
|
sleep, cold, pain, emotions, hemorrhage, exercise, hypoglycemia, infection, trauma, toxins
|
|
What monoamines are released in response to stress that signal CRH release
|
Ach and serotonin
|
|
What neurons produce CRH
|
paraventricular nucleus of the hypothalmus
|
|
Major influence of binding ACTH to the zona faciculata and zona reticulosum
|
conversion of cholesterol to pregnenolone by cholesterol dismutase. ACTH binds to a Gs receptor which stimulates adenyl cyclase, the increased cAMP activates protein kinase A which phosphorolates cholesterol dismutase.
|
|
Negative feedback of cortisol
|
on ACTH levels and CRH levels. During times of severe stress high cortisol levels are overridden by stress induced activity on the hypothalamus.
|
|
Effect of catecholomaines on isulin
|
inhibit
|
|
Cushings disease vs syndrome
|
cushings disease is excess cortisol due to a ACTH secreting tumor. Cushings syndrome is increase in cortisol by an adrenal cortical tumor
|
|
Relationship of glucose storage between cortisol and epi
|
GC cause lipolysis and muscle breakdown to supply substrates for gluconeogenisis. GC also promote the storage of said glucose as glycogen. During times of stress this stored glycogen is released by epinephrine. Epinephrin acts as the acute alarm system
|
|
What causes red strie in cushings patients
|
The catabolic effect of GC causes the breakdown of elastin which weakens the skin and allows it to stretch and subcutaneous tissues become torn.
|
|
Why is there plethora in cushings patients (red skin)
|
due to thinning of the skin as well as cortisol induced increase in bone marrow production RBCs
|
|
Steps of thyroid hormone sunthesis
|
trapping of blood iodine in the thyroid acinar cells. Oxidation of the iodine. Iodination of tyrosyl residues on thyroglobulin to form iodotyrosines. coupling of monoiodothyronine and diiodothyronine to for T3 and T4. Proteolytic cleavage of thyroglobulin to release free T3 and T4.
|
|
what causes central obesity in cushings patients
|
lipolysis activated by GC breaks down peripheral adipose tissue but GC also stimulate hunger this increase in food intake can cause central obesity and buffalo hump.
|
|
Regulation in iodine intake by thyroid acinar cells
|
the pump is activated by TSH but the amount of iodine uptake is controlled by intercellular iodine concentrations.
|
|
Thyroid peroxidase
|
located on the apical border of the acinar cell and oxidises the iodide forming iodium.
|
|
organification
|
iodide is added to an organic compound
|
|
Thyroid hormone storage
|
able to store large amounts of thyroblobulin within its colloid space.
|
|
Half life of T3 and T4
|
T4 is 7 days and T3 is 1.5 days. T3 is the more active compound and T4 is eventially turned into T3. T3 has a lower affinity for thyroxine binding globulin so it is released faster.
|
|
Where is TSH synthesized
|
in the thyrotropic cells of the anterior pituitary
|
|
Secretion pattern of TSH
|
occurs in a circadian rhythm, a surge beginning late in the afternoon and peaking before the onset of sleep. TSH is also secreted in intervals of 2-6 hours between peaks.
|
|
Effect of TSH on thyroid cells
|
stimulates every aspect of thyroid hormone production
|
|
Effects of thyroid hormone on the liver.
|
increases glycolysis and cholesterol synthesis, the cholesterol in used in the increased conversion to bile salts. Increase in the B adreonergic receptor action of gluconeogenic and glycogenolytic actions of epi
|
|
Effect of thyroid hormone on adipocytes
|
amplifies the beta adronergic effects of epinephrine on lypolysis.
|
|
Effects of thyroid hormone on muscle
|
Increases glucose uptake and stimulates protein synthesis. The B adrenergic effects increases the glycogenlysis.
|
|
Thyroid effects on the pancrease
|
needed for optimum insulin release
|
|
Effect of T3 on sympathetic nervous system
|
causes the release of norepinephrine.
|
|
Effects of thyroid hormone on BMR
|
the increase in NE release causes action potentials and the increased cellular permablity of Na and K. The increase in intercellular Na is toxic to the cell and activates Na/K ATPases to pump the Na out of the cell. At normal times the Na/K ATPase activity accounts for 20% of heat production. Increase in thyroid hormone increases these pumps and increases heat production.
|
|
Metathyroid DM
|
DM caused by increased degradation and clearance of insulin along with the increased demand for insulin. Pt will rarely develop significant DM
|
|
How do gastrointestinal hormones affect fuel metabolism
|
Regulate the availability of substrates used for fuel oxidation
|
|
Motilin
|
secreted by the M cells of the proximal small bowel increases secretion of gastric and peptic enzymes.
|
|
pancreatic peptide PP
|
reduces gastric emptying and slows intestinal motility
|
|
Peptide YY
|
inhibit gastrin secretion
|
|
Neuronal stimulants to glucogon secretion
|
both sympathetic and parasympathetic
|
|
neuronal control of insulin secretion
|
increased by vagus nerve and suppressed by sympathetic stimulation.
|
|
Meals affected on GH secretion
|
high protein of low glucose will cause secretion
|
|
Suppression test for GH hypersecretion
|
give patient oral load of glucose and measure GH levels. They should fall in a normal patient.
|
|
Function of cortisol in periods of stress
|
resorts fuel so that it can be rapidly available for fight of flight
|
|
Diabetogenic potential of chronically elevated GH
|
25% for Dm, 33% for impaired glucose tolerance. At physiology levels GH along with cortisol have permissive effects on insulin release that are intended to act like a brake to any negative effects of GH.
|
|
ELISA
|
enzyme linked immunosorbent assay. Plate is bound with Ig specific for the hormone. The hormone bonds to Ig1. floating Ig2 binds to the hormone, Ig3 is specific for Ig2. Ig3 has and attached enzyme that is activated by binding Ig2 and the enzyme produces a measurable product.
|
|
Radioimmunoassays
|
Monoclonal antibodies are produced to a hormone. They are mixed with serum form pt of unknown hormone concentration and a solution of radiolabled hormone of known concentration. The amount of labeled hormone that becomes bound is measured and teh amount of hormone in the patients serum is extrapolated from this measurement.
|